التفاصيل البيبلوغرافية
| العنوان: |
Manejo hemostático complejo en paciente con hemofilia adquirida. (Spanish) |
| Alternate Title: |
Complex haemostatic management in a patient with acquired haemophilia. (English) |
| المؤلفون: |
Benítez Hidalgo, O., Martínez García, M. F., Juárez Giménez, J. C., Suito Alcántara, M., Gironella Mesa, M., Bosch Albareda, F. |
| المصدر: |
El Farmacéutico Hospitales; jul2021, Issue 221, p36-39, 4p |
| Abstract (English): |
Acquired haemophilia A (AHA) is a rare clinical disease of autoimmune origin brought about by circulating autoantibodies that inhibit FVIII activity. Acute-onset haemorrhagic manifestations present in patients with no previous history of haemorrhage. Haemostatic treatment is currently based on the use of recombinant activated factor VII bypass agents (rFVIIa) or activated prothrombin complex concentrates (CCPa), which have been demonstrated to have high efficacy rates in published trials and registries. Thanks to the availability of these agents, early mortality due to this disease has decreased in recent years. In patients with refractory bleeding requiring haemostatic treatment, other causes that can explain the clinical picture must first be ruled out. As such, we are presenting a clinical case of a male patient diagnosed with AHA, whose haemorrhagic condition was treated using bypass agents, and who responded well following correction of his fibrinogen and factor XIII levels by administering the corresponding blood products. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
La hemofilia A adquirida (AHA) es una entidad clínica rara, de origen autoinmune, mediada por autoanticuerpos circulantes que inhiben la actividad del factor VIII (FVIII). Las manifestaciones hemorrágicas aparecen de forma aguda en pacientes sin historia previa de hemorragia. El tratamiento hemostático en la actualidad está basado en el uso de agentes bypass de tipo factor VII activado recombinante o concentrados de complejo protrombínico activado, que han demostrado altas tasas de eficacia en las series y registros publicados. Gracias a la disponibilidad de estos agentes, la mortalidad precoz de esta entidad ha disminuido en los últimos años. En pacientes con hemorragias resistentes al tratamiento hemostático se tendrán que descartar otras causas que justifiquen la clínica. Así, se presenta un caso clínico de un paciente diagnosticado de AHA cuyo cuadro hemorrágico se trató con agentes bypass, a los que respondió adecuadamente tras la corrección de sus niveles de fibrinógeno y factor XIII mediante la administración de los correspondientes hemoderivados. [ABSTRACT FROM AUTHOR] |
|
Copyright of El Farmacéutico Hospitales is the property of Ediciones Mayo and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
